Solid dose delivery vehicle and methods of making same

• US 7,744,925 B2
• Filed: 05/20/2005
• Issued: 06/29/2010
• Est. Priority Date: 12/02/1994
• Status: Expired due to Fees

• Current Assignee: Quadrant Drug Delivery Limited (Vectura Group Ltd.)
• Original Assignee: Quadrant Drug Delivery Limited (Vectura Group Ltd.)
• Inventors: Colaco, Camilo, Roser, Bruce J., Blair, Julian, Kampinga, Jaap
• Primary Examiner(s): Azpuru; Carlos A
• Application Number:
  US11/134,573
• Publication Number:
  US 20050276845A1
• Time in Patent Office: 1,866 Days
• Field of Search: 424/489, 424/499
• US Class Current: 424/499
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61K 9/145 with organic compounds
• CPC Class Codes: A61K 9/1623 Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention encompasses a therapeutic composition in solid dose form that is suitable for pulmonary administration. The therapeutic composition may comprise therapeutic particles in a glassy state. The therapeutic composition preferably comprises a bioactive material such as insulin, and a sugar alcohol. The components are optionally in solid solution. The therapeutic composition can preferably remain in a glassy state when stored at elevated temperatures, and/or extended periods.

Claims

1. A therapeutic composition in solid dose form comprising a bioactive material and a sugar alcohol, wherein

a) the bioactive material is insulin,

b) the therapeutic composition comprises therapeutic particles containing insulin homogeneously distributed in a solid solution with a sugar alcohol, wherein the therapeutic particles are in a glassy state,

c) the therapeutic composition is a powder suitable for pulmonary administration,

d) the therapeutic particles containing the insulin in the solid solution with the sugar alcohol remain in the glassy state when stored at elevated temperature for one month, wherein the elevated temperature is 60°

C., and

e) the therapeutic particles have a mean particle size of 0.5 to 5 μ

m.

2. The therapeutic composition according to claim 1, wherein the particles have a mean particle size of 1 to 4 μ

m.

3. The therapeutic composition according to claim 2, said particles further comprising a glass modifier, wherein the glass modifier is not the bioactive material.

4. The therapeutic composition according to claim 3, wherein the glass modifier is a protein.

5. The therapeutic composition according to claim 1, said therapeutic particles further comprising a physiologically acceptable inhibitor of the Maillard reaction.

6. The therapeutic composition according to claim 5, wherein the particles have a mean particle size of 1 to 4 μ

m.

7. The therapeutic composition according to claim 5, said therapeutic particles further comprising a glass modifier, wherein the glass modifier is not the bioactive material.

8. The therapeutic composition according to claim 7, wherein the glass modifier is a protein.

9. The therapeutic composition according to claim 1, said therapeutic particles further comprising an amino acid that is capable of inhibiting the Maillard reaction.

10. The therapeutic composition according to claim 9, further comprising a glass modifier, wherein the glass modifier is not the bioactive material.

11. The therapeutic composition according to claim 9, wherein the particles have a mean particle size of 1 to 4 μ

m.

12. The therapeutic composition according to claim 1, wherein the therapeutic composition is suitable for delivering the insulin by transalveolar administration.

13. The therapeutic composition according to claim 1, said therapeutic particles further comprising a glass modifier, wherein the glass modifier is not the bioactive material.

14. The therapeutic composition according to claim 13, wherein the glass modifier is a protein.

15. The therapeutic composition according to claim 1, wherein the therapeutic particles remain in a glassy state when stored for one month at 70°

C.

16. The therapeutic composition according to claim 15, wherein said therapeutic particles are spray-dried.

17. The therapeutic composition according to claim 16, said therapeutic particles further comprising an amino acid that is capable of inhibiting the Maillard reaction.

18. The therapeutic composition according to claim 17, said therapeutic particles further comprising a glass modifier, wherein the glass modifier is not the bioactive material.

19. The therapeutic composition according to claim 16, said therapeutic particles further comprising a physiologically acceptable inhibitor of the Maillard reaction.

20. The therapeutic composition according to claim 15, said therapeutic particles further comprising a glass modifier, wherein the glass modifier is not the bioactive material.

21. The therapeutic composition according to claim 15, said therapeutic particles further comprising an amino acid that is capable of inhibiting the Maillard reaction.

22. The therapeutic composition according to claim 1, wherein the therapeutic particles are spray-dried.

23. The therapeutic composition according to claim 22, said therapeutic particles further comprising a glass modifier, wherein the glass modifier is not the bioactive material.

24. The therapeutic composition according to claim 22, said therapeutic particles further comprising an amino acid that is capable of inhibiting the Maillard reaction.

25. The therapeutic composition according to claim 1, wherein said therapeutic particles additionally comprise a physiologically acceptable glass.

26. The therapeutic composition according to claim 25 wherein the physiologically acceptable glass is water soluble.

27. The therapeutic composition according to claim 25 wherein the physiologically acceptable glass in said composition comprises a water soluble physiologically acceptable carboxylate glass.

28. The therapeutic composition according to claim 26 or claim 27 wherein the composition is suitable for transalveolar delivery.

29. The therapeutic composition according to claim 28 wherein the therapeutic particles of said composition are spray-dried.

30. The therapeutic composition according to claim 29 said therapeutic particles additionally comprising an amino acid that is capable of inhibiting the Maillard reaction.

31. The therapeutic composition according to claim 26 or claim 27 wherein the therapeutic particles of said composition remain in a glassy state when stored for one month at 70°

C.

32. The therapeutic composition according to claim 28 wherein the therapeutic particles of said composition remain in a glassy state when stored for one month at 70°

C.

33. The therapeutic composition according to claim 29 wherein the therapeutic particles of said composition remain in a glassy state when stored for one month at 70°

C.

34. The therapeutic composition according to claim 30 wherein the therapeutic particles of said composition remain in a glassy state when stored for one month at 70°

C.